Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.

Pumpkin seed oil is discussed as a potential treatment for hair loss, but the study cited is criticized for using a product with multiple ingredients, making it unclear if pumpkin seed oil is effective. The conversation concludes with skepticism about the study's validity and mentions that pumpkin seeds might help with DHT blocking.

The conversation discusses hair loss treatments, focusing on iron supplements for low ferritin levels and considering finasteride and minoxidil if thinning persists. There is debate over starting with finasteride versus dutasteride, with some users advocating for dutasteride due to its potency, while others caution about potential side effects.

The conversation discusses hair loss treatments, specifically the use of oral finasteride and topical minoxidil, with the user sharing their two-year progress and routine. The user experienced initial shedding but saw improvements after six months, and they recently started taking dutasteride.

A 40-year-old woman with naturally thin and fine hair is seeking advice on over-the-counter treatments for hair loss and is open to prescription options for her upcoming doctor's appointment. She has tried biotin, Nioxin, various haircuts, and colors, and has had blood tests for deficiencies.

Hair loss's social impact, focusing on Will Smith defending Jada Pinkett Smith's alopecia. The conversation highlights double standards between men and women experiencing hair loss and emphasizes empathy.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

A user's experimentation with various hair loss treatments, including medications and topical applications; as well as their desire to experience unusual sensations through the use of drugs.

The side effects of taking finasteride as a treatment for hair loss, with particular focus on its sexual and psychiatric side effects; research has indicated that there are high and low outliers in terms of prevalence of sexual side effects, but it is usually between 3-5%, while evidence of lasting sexual side effects comes from lower quality sources.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.

The user is experiencing hair loss and has been using treatments like minoxidil, finasteride, and ciclopirox olamine. Despite these treatments, they are concerned about increased shedding, dandruff, and possible additional hair loss conditions.

A person struggling with hair loss is using treatments like dutasteride, oral minoxidil, and has had a hair transplant but remains deeply unhappy. Others suggest alternative treatments, acceptance, and focusing on other life aspects, emphasizing mental health and therapy.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.

The conversation discusses the use of microneedling as a complementary treatment for hair loss alongside oral minoxidil and dutasteride. Opinions vary on its effectiveness, with some users supporting its benefits for hair growth and others questioning its efficacy without topical minoxidil.

The user is frustrated with hair loss treatments like finasteride, minoxidil, dutasteride, and oral minoxidil, which have been ineffective and caused scalp itching. They are skeptical about these treatments' effectiveness and consider alternative options like ketoconazole shampoo and RU58841.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Young individuals experiencing hair loss are discussing their experiences with treatments like minoxidil and finasteride. Some report positive results with finasteride, despite side effects, while others share tips for managing minoxidil-related dandruff.

A 36-year-old man with androgenetic alopecia suspects copper and zinc deficiencies may be accelerating hair loss and is supplementing copper to address this. He is also monitoring blood sugar levels due to previous prediabetes concerns and plans to test for insulin resistance.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Topical dutasteride with microneedling is effective for androgenetic alopecia, improving hair thickness and density. Further research is needed to confirm long-term efficacy.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

Dutasteride can slow hair loss and potentially stabilize it, but results vary by individual. Minoxidil and dutasteride may lose effectiveness over time, and hair loss might continue despite treatment.

A 26-year-old male is considering starting the "Big 3" treatments for hair thinning, which include Minoxidil, finasteride, and RU58841, and is unsure whether to begin these treatments or consult a dermatologist first.

The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.